Newsfeeds - Spark Newswire

1 minute read

Zhongchao Announces Medical Education Services Agreement With AbbVie Subsidiary; Terms Not Disclosed

Today, 6:17 AM

Zhongchao Inc. (NASDAQ:ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering online healthcare information, professional training and educational services, today announced the

ABBV

3 minute read

IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings

By Chris Katje

Today, 6:17 AM

This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.

ABBV

1 minute read

AbbVie-Roche’s Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment

By Vandana Singh

Today, 6:17 AM

Genentech, a unit of Roche Holdings AG (OTC:RHHBY), and its collaborating partner AbbVie Inc (NYSE:ABBV) have announced long-term follow-up data from two Phase 3…

ABBV

1 minute read

‘Halftime Report’ Traders Share Their Thoughts On Gilead, IBM And More

By Craig Jones

Today, 6:17 AM

On CNBC's "Fast Money Halftime Report," Josh Brown said ICICI Bank Ltd (NYSE: IBN) looks like it's going higher.

ABBV

4 minute read

FDA
News

AbbVie Offers Extended Long-Term Data From Phase 3 Study Of IMBRUVICA vs Chlorambucil For Patents With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma At American Society Of Clinical Oncology Jun. 4

By Benzinga Newsdesk

Today, 6:17 AM

With up to seven years of data, progression-free and overall survival benefits continue to be observed with first-line single-agent IMBRUVICA treatment in CLL patients including selected patients with or without

ABBV

1 minute read

Lilly’s Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial

By Vandana Singh

Today, 6:17 AM

Eli Lilly And Co (NYSE:LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib)…

ABBV

1 minute read

Almost Half of Crohn’s Disease Patients Achieved Endoscopic Response After One Year of Maintenance Treatment with AbbVie’s Risankizumab

By Vandana Singh

Today, 6:17 AM

AbbVie Inc (NYSE: ABBV) has announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing Skyrizi (risankizumab) achieved the co-primary endpoints of endoscopic response and clinical remission at one year in Crohn's disease.

ABBV

1 minute read

Uncategorized

Abbvie Highlights Lancet Publication Highlighting Pivotal Global Phase 3 Program Evaluating RINVOQ In Atopic Dermatitis

By Benzinga Newsdesk

Today, 6:17 AM

AbbVie (NYSE:ABBV) today announced The Lancet published primary analysis results from the pivotal global Phase 3 clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating

ABBV

6 minute read

Uncategorized

The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings

By Shanthi Rexaline

Today, 6:17 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)

ABBV

4 minute read

Uncategorized

9 Health Care Stocks Showing Unusual Options Activity In Today’s Session

By Benzinga Insights

Today, 6:17 AM

This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to hyperbolic or underperforming levels.

ABBV